ACAD Q2 2024 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$242M+46.4% YoY

Gross Profit

$224M92.5% margin

Operating Income

$30M12.6% margin

Net Income

$33M13.8% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

+17.6%

Cash Flow

Operating Cash Flow

$25M

Free Cash Flow

$25M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$914M

Total Liabilities

$397M

Stockholders' Equity

$517M

Cash & Equivalents

$177M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$242M	$165M	+46.4%
Gross Profit	$224M	$158M	+41.8%
Operating Income	$30M	$3M	+902.2%
Net Income	$33M	$1M	+2897.2%